Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Endocrine Surgery

Building Your Specialized Care Team

At a Glance

Treating rare thyroid cancers like ATC, MTC, and PDTC requires a multidisciplinary team at a high-volume cancer center. Traveling to an expert center provides access to specialized surgeons, tumor boards, and clinical trials that are critical for achieving the best outcomes.

Because rare thyroid cancers—like Anaplastic (ATC), Medullary (MTC), and Poorly Differentiated (PDTC)—are so uncommon, most general doctors and local hospitals may only see one case every few years. Managing these aggressive diseases requires a “team of teams” [1][2].

Evidence shows that patients treated at high-volume, specialized cancer centers often have better outcomes and lower rates of surgical complications [3][4]. In the world of rare disease, traveling to an expert center is not just an option; it is often a necessity for receiving the current standard of care [5][6].

Your Core Multidisciplinary Team

A “multidisciplinary team” (MDT) is a group of specialists who meet regularly to coordinate every aspect of your care [2][5]. Your team should include:

  • Head and Neck / Endocrine Surgeon: A specialist who performs a high volume of complex thyroid surgeries (often 30 to over 100 per year) [3][5].
  • Endocrine Oncologist: A medical oncologist who specializes in “targeted” systemic therapies, such as RET or BRAF inhibitors, rather than just traditional chemotherapy [7][8].
  • Endocrinologist: A specialist who manages your thyroid hormone levels and monitors blood markers like Calcitonin or CEA [2].
  • Endocrine Pathologist: This is the most “invisible” but critical team member. They are specialists who re-review your tissue slides to ensure the subtype (e.g., DHGTC vs. PDTC) is exactly correct [9][2].
  • Radiation Oncologist: A specialist who uses targeted beams of energy to treat any remaining cancer in the neck or other areas [10][11].

Why High-Volume Centers Matter

Specialized centers have infrastructure that smaller hospitals lack. This includes:

  • Tumor Boards: A weekly meeting where all the specialists listed above sit in a room together to debate the best path forward for your specific case [2][12].
  • Fast-Track Protocols: For aggressive cancers like ATC, specialized centers use “FAST” protocols to get you through imaging, pathology, and into treatment in days, not weeks [13][14].
  • Clinical Trials: Many of the most effective new treatments for rare thyroid cancers are only available through clinical trials at academic institutions [15][16].

What to Bring to Your First Consult

When seeking a second opinion or starting at a new center, do not assume they have your records. You should physically bring [1][17]:

  1. Original Pathology Slides: Not just the paper report, but the actual glass slides (or the “paraffin blocks” they are made from) for the new center’s pathologist to review [1].
  2. Molecular/NGS Reports: Any genetic testing results that show mutations like BRAF, RET, or TERT [6][17].
  3. Digital Imaging: A disc or digital link containing your CT, PET, and ultrasound scans [18].

The Role of Clinical Trials

For rare cancers, clinical trials are often not a “last resort.” They are frequently the way to access the newest, most effective precision medicines (like the latest RET or NTRK inhibitors) before they are widely available [7][16]. In some cases, such as ATC, being on a clinical trial for neoadjuvant (pre-surgery) therapy can make a tumor that was previously “un-operable” small enough to safely remove [19][20].

Common questions in this guide

Why do I need a specialized center for rare thyroid cancer?
Rare thyroid cancers are uncommon, meaning local hospitals may rarely see them. Specialized centers offer multidisciplinary tumor boards, fast-track treatment protocols, and dedicated experts, which have been shown to significantly improve patient outcomes and lower complication rates.
Who should be on my rare thyroid cancer care team?
Your multidisciplinary team should include a high-volume head and neck or endocrine surgeon, an endocrine oncologist for targeted therapies, an endocrinologist to monitor hormone levels, a radiation oncologist, and an endocrine pathologist to accurately identify your cancer subtype.
What should I bring to a second opinion consultation?
You should bring your original glass pathology slides, molecular and genetic testing reports, and a digital disc or link containing all your CT, PET, and ultrasound scans. Do not assume the new center automatically has your previous medical records.
Are clinical trials a last resort for rare thyroid cancer?
No, clinical trials are often not a last resort. For rare thyroid cancers, trials frequently offer early access to the newest, most effective precision medicines before they are widely available. In some cases, trial therapies can shrink an inoperable tumor enough to make surgery possible.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do you participate in a weekly multidisciplinary thyroid tumor board to discuss complex cases like mine?
  2. 2.How many thyroid surgeries do you perform each year, and what percentage of those are for rare or aggressive types like mine?
  3. 3.Who is the pathologist on my team, and do they specialize specifically in endocrine or head and neck cancers?
  4. 4.Does this center have active clinical trials for my specific type of thyroid cancer, especially for targeted or 'neoadjuvant' therapies?
  5. 5.Who is my main point of contact if my symptoms (like breathing or swallowing) change rapidly between appointments?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Liver Mass as First-Time Diagnosis of Sarcomatoid Anaplastic Thyroid Carcinoma: A Rare Malignancy Presenting at an Unexpected Body Site.

    Kamashki A, Rivera M, Sturgis CD

    The American journal of case reports 2023; (24()):e941838 doi:10.12659/AJCR.941838.

    PMID: 38041397
  2. 2

    Aggressive Types of Malignant Thyroid Neoplasms.

    Boudina M, Zisimopoulou E, Xirou P, Chrisoulidou A

    Journal of clinical medicine 2024; (13(20)) doi:10.3390/jcm13206119.

    PMID: 39458070
  3. 3

    Updates on the Management of Thyroid Cancer.

    Araque KA, Gubbi S, Klubo-Gwiezdzinska J

    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2020; (52(8)):562-577 doi:10.1055/a-1089-7870.

    PMID: 32040962
  4. 4

    Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid carcinoma.

    Kwon H, Kim WG, Sung TY, et al.

    Journal of surgical oncology 2016; (113(2)):152-8 doi:10.1002/jso.24126.

    PMID: 26799259
  5. 5

    Diagnostics and treatment of differentiated thyroid carcinoma in children - Guidelines of the Polish National Scientific Societies, 2024 Update.

    Handkiewicz-Junak D, Niedziela M, Lewiński A, et al.

    Endokrynologia Polska 2024; (75(6)):565-591 doi:10.5603/ep.103845.

    PMID: 39829212
  6. 6

    Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management.

    Mete O, Boucher A, Schrader KA, et al.

    Endocrine pathology 2024; (35(4)):293-308 doi:10.1007/s12022-024-09836-x.

    PMID: 39579327
  7. 7

    Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.

    Hadoux J, Elisei R, Brose MS, et al.

    The New England journal of medicine 2023; (389(20)):1851-1861 doi:10.1056/NEJMoa2309719.

    PMID: 37870969
  8. 8

    PD-1 Blockade in Anaplastic Thyroid Carcinoma.

    Capdevila J, Wirth LJ, Ernst T, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(23)):2620-2627 doi:10.1200/JCO.19.02727.

    PMID: 32364844
  9. 9

    SEAP-GETNE consensus on prognostic and predictive molecular biomarkers in thyroid cancer.

    Ruz-Caracuel I, Alonso-Gordoa T, Hernández S, et al.

    Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia 2026; (59(2)):100859 doi:10.1016/j.patol.2026.100859.

    PMID: 41747300
  10. 10

    Combination of Novel Therapies and New Attempts in Anaplastic Thyroid Cancer.

    Li W, Li Y, Li J, Pang H

    Technology in cancer research & treatment 2023; (22()):15330338231169870 doi:10.1177/15330338231169870.

    PMID: 37122242
  11. 11

    An Update of the Appropriate Treatment Strategies in Anaplastic Thyroid Cancer: A Population-Based Study of 735 Patients.

    Huang NS, Shi X, Lei BW, et al.

    International journal of endocrinology 2019; (2019()):8428547 doi:10.1155/2019/8428547.

    PMID: 30915116
  12. 12

    Anaplastic Thyroid Carcinoma: An Update.

    Jannin A, Escande A, Al Ghuzlan A, et al.

    Cancers 2022; (14(4)) doi:10.3390/cancers14041061.

    PMID: 35205809
  13. 13

    Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement.

    Hamidi S, Dadu R, Zafereo ME, et al.

    JAMA oncology 2024; (10(9)):1264-1271 doi:10.1001/jamaoncol.2024.2133.

    PMID: 38990526
  14. 14

    Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report.

    Barbaro D, Forleo R, Profilo MA, et al.

    Frontiers in endocrinology 2024; (15()):1389294 doi:10.3389/fendo.2024.1389294.

    PMID: 39045273
  15. 15

    Promising Therapeutic Targets for Recurrent/Metastatic Anaplastic Thyroid Cancer.

    Abdalla AS, Rahman M, Khan SA

    Current treatment options in oncology 2024; (25(7)):869-884 doi:10.1007/s11864-024-01219-y.

    PMID: 38862695
  16. 16

    Recent advances and emerging therapies in anaplastic thyroid carcinoma.

    Cabanillas ME, Zafereo M, Williams MD, et al.

    F1000Research 2018; (7()) doi:10.12688/f1000research.13124.1.

    PMID: 31583077
  17. 17

    Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.

    Waguespack SG, Drilon A, Lin JJ, et al.

    European journal of endocrinology 2022; (186(6)):631-643 doi:10.1530/EJE-21-1259.

    PMID: 35333737
  18. 18

    Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [18F]FDG PET/CT.

    Ferrari C, Santo G, Ruta R, et al.

    Diagnostics (Basel, Switzerland) 2021; (11(8)) doi:10.3390/diagnostics11081417.

    PMID: 34441351
  19. 19

    Mutation-based, short-term "neoadjuvant" treatment allows resectability in stage IVB and C anaplastic thyroid cancer.

    Maurer E, Eilsberger F, Wächter S, et al.

    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2023; (280(3)):1509-1518 doi:10.1007/s00405-023-07827-y.

    PMID: 36637521
  20. 20

    The American Thyroid Association (ATA) integrates molecular testing into its framework for managing patients with anaplastic thyroid carcinoma (ATC): Update on the 2021 ATA ATC guidelines.

    Silver Karcioglu A, Iwata AJ, Pusztaszeri M, et al.

    Cancer cytopathology 2022; (130(3)):174-180 doi:10.1002/cncy.22519.

    PMID: 34618407

This page provides educational information on building a care team for rare thyroid cancers. It does not replace professional medical advice, and you should always consult your oncologist or surgeon regarding your specific treatment plan.

Get notified when new evidence is published on Rare thyroid carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.